

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :	A1	(11) International Publication Number: <b>WO 99/27103</b>
C12N 15/19, C07K 14/52, 16/24, 16/42, A61K 38/19, 48/00, A01K 67/027		(43) International Publication Date: 3 June 1999 (03.06.99)
(21) International Application Number: PCT/US98/25228		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 25 November 1998 (25.11.98)		
(30) Priority Data: 08/979,156 26 November 1997 (26.11.97) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).		
(72) Inventors: CONKLIN, Darrell, C.; Apartment 2, 2332 Minor Avenue East, Seattle, WA 98102 (US). HALDEMAN, Betty, A.; 7559 30th Avenue N.E., Seattle, WA 98115 (US). GROSSMANN, Angelika; 2809 N.E. 60th, Seattle, WA 98115 (US).		
(74) Agent: LUNN, Paul, G.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).		

(54) Title: MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10

## (57) Abstract

A mammalian cytokine-like polypeptide, called Zcyto10, polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10

## BACKGROUND OF THE INVENTION

Proliferation and differentiation of cells of multicellular organisms are controlled by hormones and polypeptide growth factors. These diffusible molecules allow cells to communicate with each other and act in concert to form cells and organs, and to repair and regenerate damaged tissue. Examples of hormones and growth factors include the steroid hormones (e.g. estrogen, testosterone), parathyroid hormone, follicle stimulating hormone, the interleukins, platelet derived growth factor (PDGF), epidermal growth factor (EGF), granulocyte-macrophage colony stimulating factor (GM-CSF), erythropoietin (EPO) and calcitonin.

Hormones and growth factors influence cellular metabolism by binding to proteins. Proteins may be integral membrane proteins that are linked to signaling pathways within the cell, such as second messenger systems. Other classes of proteins are soluble molecules.

Of particular interest are cytokines, molecules that promote the proliferation and/or differentiation of cells. Examples of cytokines include erythropoietin (EPO), which stimulates the development of red blood cells; thrombopoietin (TPO), which stimulates development of cells of the megakaryocyte lineage; and granulocyte-colony stimulating factor (G-CSF), which stimulates development of neutrophils. These cytokines are useful in restoring normal blood cell levels in patients.

suffering from anemia or receiving chemotherapy for cancer. The demonstrated *in vivo* activities of these cytokines illustrates the enormous clinical potential of, and need for, other cytokines, cytokine agonists, and 5 cytokine antagonists.

#### SUMMARY OF THE INVENTION

The present invention addresses this need by 10 providing a novel polypeptide and related compositions and methods. Within one aspect, the present invention provides an isolated polynucleotide encoding a mammalian four alpha helix cytokine termed Zcyt010. The human Zcyt010 polypeptide is comprised of a sequence of 176 15 amino acids with the initial Met as shown in SEQ ID NO:1 and SEQ ID NO:2. It is believed that amino residues 1-24 are signal sequence, and the mature Zcyt010 polypeptide is represented by the amino acid sequence comprised of residues 25, a leucine, through amino acid residue 176, a glutamic acid residue, also defined by SEQ ID NO:12. 20 Another embodiment of the present invention is defined by the sequences of SEQ ID NO: 3 and SEQ ID NO: 4. The polypeptide of SEQ ID NO: 4 is comprised of 151 amino acid residues wherein amino acids 1-24 comprise a signal 25 sequence and the mature sequence is comprised of amino acid residues 25, a leucine, through amino acid 151 a glutamic acid, also defined by SEQ ID NO:13. Another active variant is comprised of amino acid residues 33, a cysteine, through amino acid residue 176 of SEQ ID NO:2. 30 This variant is also defined by SEQ ID NO:26.

Mouse Zcyt010 is also a polypeptide comprised of 176 amino acid residues as defined by SEQ ID NOS: 18 and 19. Mouse Zcyt010 has a signal sequence extending from amino 35 acid residue 1, a methionine, extending to and including amino acid residue 24, a glycine of SEQ ID NO:19. Thus, the mature mouse Zcyt010 extends from amino acid residue

25, a leucine, to and including amino acid residue 176 a  
leucine of SEQ ID NO:19, also defined by SEQ ID NO:20.  
Another active variant is believed to extend from amino  
acid 33, a cysteine, through amino acid 176, of SEQ ID  
5 NO:19. This variant is also defined by SEQ ID NO:25.  
Within an additional embodiment, the polypeptide further  
comprises an affinity tag.

A variant of mouse Zcyt010 is defined by SEQ ID NOS:  
10 33 and 34. This variant is 154 amino acid residues in  
length and has a signal sequence extending from amino  
acid residue 1, a methionine, to and including amino acid  
residue 24, a glycine, of SEQ ID NO:34. Thus, the mature  
sequence extends from amino acid residue 25, a leucine,  
15 to and including amino acid residue 154, a leucine, of  
SEQ ID NO:34. The mature sequence is also defined by SEQ  
ID NO:35.

Within a second aspect of the invention there is  
20 provided an expression vector comprising (a) a  
transcription promoter; (b) a DNA segment encoding  
Zcyt010 polypeptide, and (c) a transcription terminator,  
wherein the promoter, DNA segment, and terminator are  
operably linked.

25

Within a third aspect of the invention there is  
provided a cultured eukaryotic or prokaryotic cell into  
which has been introduced an expression vector as  
disclosed above, wherein said cell expresses a  
30 polypeptide encoded by the DNA segment.

Within a further aspect of the invention there  
is provided a chimeric polypeptide consisting essentially  
of a first portion and a second portion joined by a  
35 peptide bond. The first portion of the chimeric  
polypeptide consists essentially of (a) a Zcyt010  
polypeptide as shown in SEQ ID NO: 2 (b) allelic variants

of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26 SEQ ID NO:34 or SEQ ID NO:35; and (c) protein polypeptides that are at least 90% identical to (a) or  
5 (b). The second portion of the chimeric polypeptide consists essentially of another polypeptide such as an affinity tag. Within one embodiment the affinity tag is an immunoglobulin F<sub>C</sub> polypeptide. The invention also provides expression vectors encoding the chimeric  
10 polypeptides and host cells transfected to produce the chimeric polypeptides.

Within an additional aspect of the invention there is provided an antibody that specifically binds to  
15 a Zcyt010 polypeptide as disclosed above, and also an anti-idiotypic antibody which neutralizes the antibody to a Zcyt010 polypeptide.

Within another aspect of the present invention  
20 there is provided a pharmaceutical composition comprising purified Zcyt010 polypeptide in combination with a pharmaceutically acceptable vehicle. Such compositions may be useful for modulating of cell proliferation, cell differentiation or cytokine production in the prevention  
25 or treatment of conditions characterized by improper cell proliferation, cell differentiation or cytokine production, as are further discussed herein. More specifically, Zcyt010 polypeptide may be useful in the prevention or treatment of autoimmune diseases by  
30 inhibiting a cellular immune response. Autoimmune diseases which may be amenable to Zcyt010 treatment include IDDM, multiple sclerosis, rheumatoid arthritis and the like. Also, Zcyt010 polypeptides of the present invention may be useful in inhibiting cancer cell growth  
35 or proliferation.

Zcyto10 polypeptides of the present invention may also stimulate the immune system to better combat microbial or viral infections. In particular, Zcyto10 can be administered systemically to increase platelet production by an individual. Moreover, Zcyto10 polypeptides of the present invention may be used in trachea-specific or tracheobronchial-specific applications, such as in the maintenance or wound repair of the tracheobronchial epithelium or cells underlying the same, in regulating mucous production or mucociliary clearance of debris or in treatment of asthma, bronchitis or other diseases of the tracheobronchial tract. It may also enhance wound healing and promote regeneration of affected tissues which may be especially useful in the treatment of periodontal disease. Furthermore, Zcyto10 polypeptides can be used to treat skin conditions such as psoriasis, eczema and dry skin in general.

An additional embodiment of the present invention relates to a peptide or polypeptide which has the amino acid sequence of an epitope-bearing portion of a Zcyto10 polypeptide having an amino acid sequence described above. Peptides or polypeptides having the amino acid sequence of an epitope-bearing portion of a Zcyto10 polypeptide of the present invention include portions of such polypeptides with at least nine, preferably at least 15 and more preferably at least 30 to 50 amino acids, although epitope-bearing polypeptides of any length up to and including the entire amino acid sequence of a polypeptide of the present invention described above are also included in the present invention. Also claimed are any of these polypeptides that are fused to another polypeptide or carrier molecule. Such epitope variants include but are not limited to SEQ ID NOS: 25-32. Antibodies produced from these epitope-bearing portions of Zcyto10 can be used in purifying Zcyto10 from cell culture medium.

These and other aspects of the invention will become evident upon reference to the following detailed description and the attached drawing.

5

#### DETAILED DESCRIPTION OF THE INVENTION

The teachings of all the references cited herein are  
10 incorporated in their entirety by reference.

Prior to setting forth the invention in detail, it may be helpful to the understanding thereof to define the following terms:

15

The term "affinity tag" is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of 20 the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A, Nilsson et al., *EMBO J.* 4:1075 (1985); 25 Nilsson et al., *Methods Enzymol.* 198:3 (1991), glutathione S transferase, Smith and Johnson, *Gene* 67:31 (1988), Glu-Glu affinity tag, Grussenmeyer et al., *Proc. Natl. Acad. Sci. USA* 82:7952-4 (1985), substance P, Flag<sup>TM</sup> peptide, Hopp et al., *Biotechnology* 6:1204-1210 (1988), 30 streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., *Protein Expression and Purification* 2: 95-107 (1991). DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

35

The term "allelic variant" is used herein to denote any of two or more alternative forms of a gene occupying

the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may 5 encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

The terms "amino-terminal" and "carboxyl-terminal" 10 are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl- 15 terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.

20 The term "complement/anti-complement pair" denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement 25 pair. Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the 30 complement/anti-complement pair preferably has a binding affinity of  $<10^9$  M<sup>-1</sup>.

The term "complements of a polynucleotide molecule" 35 is a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

- The term "contig" denotes a polynucleotide that has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences are said to "overlap" a given stretch of polynucleotide sequence either in their entirety or along a partial stretch of the polynucleotide. For example, representative contigs to the polynucleotide sequence 5'-ATGGCTTAGCTT-3' are 5'-  
5 TAGCTTgagtct-3' and 3'-gtcgacTACCGA-5'.
- 10 The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more degenerate codons. (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of  
15 nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).

- 20 The term "expression vector" is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of  
25 replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
- 30 The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered  
35 protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA

molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The 5 identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, *Nature* 316:774-78 (1985).

An "isolated" polypeptide or protein is a 10 polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is 15 preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. When used in this context, the term "isolated" does not exclude the presence of the same polypeptide in alternative physical 20 forms, such as dimers or alternatively glycosylated or derivatized forms. —

The term "operably linked", when referring to DNA segments, indicates that the segments are arranged so 25 that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.

30 The term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

35

"Paralogs" are distinct but structurally related proteins made by an organism. Paralogs are believed to

arise through gene duplication. For example,  $\alpha$ -globin,  $\beta$ -globin, and myoglobin are paralogs of each other.

- A "polynucleotide" is a single- or double-stranded 5 polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules. Sizes of 10 polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded 15 molecules it is used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may 20 be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired. Such unpaired ends will in general not exceed 20 nt in length.
- A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides". 25
- The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' 30 non-coding regions of genes.

A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be 5 added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

10

The term "receptor" denotes a cell-associated protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell. Membrane-bound receptors are characterized by a 15 multi-domain structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between 20 the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, 25 increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid 30 stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).

35

The term "secretory signal sequence" denotes a DNA sequence that encodes a polypeptide (a "secretory

peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

The term "splice variant" is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene.

Molecular weights and lengths of polymers determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to  $\pm 10\%$ .

conserved amino acids in the helix D of Zcyt010 can be used as a tool to identify new family members. Helix D has the most highly conserved having about 32% identity with the helix D of IL-10. For instance, reverse transcription-polymerase chain reaction (RT-PCR) can be used to amplify sequences encoding the conserved [the domain, region or motif from above] from RNA obtained from a variety of tissue sources or cell lines. In particular, highly degenerate primers designed from the Zcyt010 sequences are useful for this purpose.

Within preferred embodiments of the invention the isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:18, SEQ ID NO:33 or a sequence complementary thereto, under stringent conditions. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typical stringent conditions are those in which the salt concentration is about 0.02 M or less at pH 7 and the temperature is at least about 60°C. As previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for isolating DNA and RNA are well known in the art. Total RNA can be prepared using guanidine HCl extraction followed by isolation by centrifugation in a CsCl gradient [Chirgwin *et al.*, *Biochemistry* 18:52-94, (1979)]. Poly (A)<sup>+</sup> RNA is prepared from total RNA using the method of Aviv and Leder, *Proc. Natl. Acad. Sci. USA* 69:1408-1412 (1972). Complementary DNA (cDNA) is prepared from poly(A)<sup>+</sup> RNA using known methods. Polynucleotides encoding Zcyt010 polypeptides are then identified and isolated by, for example, hybridization or PCR.

Additionally, the polynucleotides of the present invention can be synthesized using a DNA synthesizer. Currently the method of choice is the phosphoramidite method. If chemically synthesized double stranded DNA is required for an application such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately. The production of short genes (60 to 80 bp) is technically straightforward and can be accomplished by synthesizing the complementary strands and then annealing them. For the production of longer genes (>300 bp), however, special strategies must be

invoked, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%. To overcome this problem, synthetic genes (double-stranded) are assembled in modular form from single-stranded fragments 5 that are from 20 to 100 nucleotides in length. See Glick, Bernard R. and Jack J. Pasternak, *Molecular Biotechnology, Principles & Applications of Recombinant DNA*, (ASM Press, Washington, D.C. 1994), Itakura, K. et al. Synthesis and use of synthetic oligonucleotides.

10 Annu. Rev. Biochem. 53 : 323-356 (1984), and Climie, S. et al. Chemical synthesis of the thymidylate synthase gene. Proc. Natl. Acad. Sci. USA 87 :633-637 (1990).

Those skilled in the art will recognize that the 15 sequences disclosed in SEQ ID NOs:1, 2, 3 and 4 represent a two alleles of the human, and SEQ ID NOs:18, 19, 33 and 34 represent two alleles of the mouse. Additional allelic variants of these sequences can be cloned by probing cDNA or genomic libraries from different 20 individuals according to standard procedures. Allelic variants of this sequence can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Allelic variants of the DNA sequence shown in SEQ ID NO:1, including those containing 25 silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of SEQ ID NO:2. cDNAs generated from alternatively spliced mRNAs, which retain the properties 30 of the Zcyt010 polypeptide are included within the scope of the present invention, as are polypeptides encoded by such cDNAs and mRNAs. Allelic variants and splice variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals or 35 tissues according to standard procedures known in the art.

The present invention further provides counterpart proteins and polynucleotides from other species ("species orthologs"). Of particular interest 5 are Zcyt010 polypeptides from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primates. Species orthologs of the human Zcyt010 protein can be cloned using information and compositions provided by the present invention in 10 combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses the protein. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed 15 herein. A library is then prepared from mRNA of a positive tissue or cell line. A protein-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human or mouse cDNA or with one or more sets of degenerate probes based on the 20 disclosed sequences. A cDNA can also be cloned using the polymerase chain reaction, or PCR (Mullis et al. U.S. Patent No. 4,683,202), using primers designed from the sequences disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect 25 host cells, and expression of the cDNA of interest can be detected with an antibody to the protein. Similar techniques can also be applied to the isolation of genomic clones. As used and claimed, the language "an isolated polynucleotide which encodes a polypeptide, said 30 polynucleotide being defined by SEQ ID NOS: 2, 4 12, 13, 19, 20, 25, 26, 34 and 35" includes all allelic variants and species orthologs of these polypeptides.

The present invention also provides isolated 35 protein polypeptides that are substantially identical to the protein polypeptides of SEQ ID NO: 2 and its species orthologs. By "isolated" is meant a protein or

polypeptide that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly 5 other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure. The term "substantially identical" is used herein to denote polypeptides having 50%, preferably 60%, more 10 preferably at least 80%, sequence identity to the sequence shown in SEQ ID NOS: 2, 4 12, 13, 19, 20, 25, 26, 34 and 35, or their species orthologs. Such polypeptides will more preferably be at least 90% 15 identical, and most preferably 95% or more identical to SEQ ID NO:2, or its species orthologs. Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., *Bull. Math. Bio.* 48: 603-616 (1986) and Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915-10919 (1992). Briefly, two amino acid 20 sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blossom 62" scoring matrix of Henikoff and Henikoff (*ibid.*) as shown in Table 1 (amino acids are indicated by the standard one-letter codes). 25 The percent identity is then calculated as:

Total number of identical matches

  x100

30 [length of the longer sequence plus the  
number of gaps introduced into the longer  
sequence in order to align the two  
sequences]

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
	A	4																		
	R	-1	5																	
	N	-2	0	6																
	D	-2	-2	1	6															
	C	0	-3	-3	-3	9														
	Q	-1	1	0	0	-3	5													
10	E	-1	0	0	2	-4	2	5												
	G	0	-2	0	-1	-3	-2	-2	6											
	H	-2	0	1	-1	-3	0	0	-2	8										
	I	-1	-3	-3	-1	-3	-3	-4	-3	4										
	L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4								
	K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5							
	M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5						
	F	-2	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
	P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7				
	S	1	-1	1	0	-1	0	0	-1	-2	0	-1	-2	-1	4					
	T	0	-1	0	-1	-1	-1	-2	-2	-1	-1	-1	-2	-1	1	5				
	W	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	-4	-3	-2	11			
	Y	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
	V	0	-3	-3	-3	-1	-2	-2	-3	3	1	-2	1	-1	-2	0	-3	-1	4	

Table 1

Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above.

5 Variant Zcyt010 polypeptides or substantially identical proteins and polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see  
10 Table 2) and other substitutions that do not significantly affect the folding or activity of the protein or polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue,  
15 a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification (an affinity tag), such as a poly-histidine tract, protein A, Nilsson et al., *EMBO J.* 4:1075 (1985); Nilsson et al., *Methods Enzymol.* 198:3 (1991), glutathione S transferase, Smith  
20 and Johnson, *Gene* 67:31 (1988), or other antigenic epitope or binding domain. See, in general Ford et al., *Protein Expression and Purification* 2: 95-107 (1991). DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

25

Table 2

<u>Conservative amino acid substitutions</u>	
Basic:	arginine
	lysine
	histidine
30 Acidic:	glutamic acid
	aspartic acid
Polar:	glutamine
	asparagine
35 Hydrophobic:	leucine
	isoleucine
	valine

Table 2, continued

	Aromatic:	phenylalanine tryptophan tyrosine
5	Small:	glycine alanine serine threonine methionine
10		

The present invention further provides a variety of other polypeptide fusions [and related multimeric proteins comprising one or more polypeptide fusions]. For example, a Zcyto10 polypeptide can be prepared as a fusion 15 to a dimerizing protein as disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584. Preferred dimerizing proteins in this regard include immunoglobulin constant region domains. Immunoglobulin-Zcyto10 polypeptide fusions can be expressed in genetically engineered cells [to produce a 20 variety of multimeric Zcyto10 analogs]. Auxiliary domains can be fused to Zcyto10 polypeptides to target them to specific cells, tissues, or macromolecules (e.g., collagen). For example, a Zcyto10 polypeptide or protein could be targeted to a predetermined cell type by fusing a 25 polypeptide to a ligand that specifically binds to a receptor on the surface of the target cell. In this way, polypeptides and proteins can be targeted for therapeutic or diagnostic purposes. A Zcyto10 polypeptide can be fused to two or more moieties, such as an affinity tag for 30 purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al., *Connective Tissue Research* 34:1-9 (1996).

35 The proteins of the present invention can also comprise non-naturally occurring amino acid residues. Non-naturally occurring amino acids include, without

limitation, *trans*-3-methylproline, 2,4-methanoproline, *cis*-4-hydroxyproline, *trans*-4-hydroxyproline, *N*-methylglycine, *allo*-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine,

5 nitroglutamine, homoglutamine, pipecolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4-methylproline, 3,3-dimethylproline, *tert*-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several

10 methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing

15 amino acids and aminoacylating tRNA are known in the art. Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis [Cunningham and Wells, *Science* 244:

20 1081-1085 (1989)]; Bass *et al.*, *Proc. Natl. Acad. Sci. USA* 88:4498-4502 (1991). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g., ligand binding and signal

25 transduction) to identify amino acid residues that are critical to the activity of the molecule. Sites of ligand-protein interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography

30 or photoaffinity labeling. See, for example, de Vos *et al.*, *Science* 255:306-312 (1992); Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); Wlodaver *et al.*, *FEBS Lett.* 309:59-64 (1992). The identities of essential amino acids can also be inferred from analysis of homologies with

35 related proteins.

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer, *Science* 241:53-57 (1988) or Bowie and Sauer *Proc. Natl. Acad. Sci. USA* 86:2152-2156 (1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., *Biochem.* 30:10832-10837 (1991); Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis, Derbyshire et al., *Gene* 46:145 (1986); Ner et al., *DNA* 7:127 (1988).

Mutagenesis methods as disclosed above can be combined with high-throughput screening methods to detect activity of cloned, mutagenized proteins in host cells. Preferred assays in this regard include cell proliferation assays and biosensor-based ligand-binding assays, which are described below. Mutagenized DNA molecules that encode active proteins or portions thereof (e.g., ligand-binding fragments) can be recovered from the host cells and rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

30

Using the methods discussed above, one of ordinary skill in the art can prepare a variety of polypeptides that are substantially identical to SEQ ID NOS: 2, 4 12, 13, 19, 20, 25, 26, 34 and 35 or allelic variants thereof and retain the properties of the wild-type protein. As expressed and claimed herein the language, "a polypeptide as defined by SEQ ID NO: 2"

includes all allelic variants and species orthologs of the polypeptide.

The protein polypeptides of the present invention, including full-length proteins, protein fragments (e.g. ligand-binding fragments), and fusion polypeptides can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred.

Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and Ausubel *et al.*, *ibid.*

20

Polynucleotides, generally a cDNA sequence, of the present invention encode the above-described polypeptides. A DNA sequence which encodes a polypeptide of the present invention is comprised of a series of codons, each amino acid residue of the polypeptide being encoded by a codon and each codon being comprised of three nucleotides. The amino acid residues are encoded by their respective codons as follows.

30 Alanine (Ala) is encoded by GCA, GCC, GCG or GCT;

Cysteine (Cys) is encoded by TGC or TGT;  
Aspartic acid (Asp) is encoded by GAC or GAT;  
Glutamic acid (Glu) is encoded by GAA or GAG;  
35 Phenylalanine (Phe) is encoded by TTC or TTT;  
Glycine (Gly) is encoded by GGA, GGC, GGG or GGT;

Histidine (His) is encoded by CAC or CAT;  
Isoleucine (Ile) is encoded by ATA, ATC or ATT;  
Lysine (Lys) is encoded by AAA, or AAG;  
Leucine (Leu) is encoded by TTA, TTG, CTA, CTC,  
5 CTG or CTT;  
Methionine (Met) is encoded by ATG;  
Asparagine (Asn) is encoded by AAC or AAT;  
Proline (Pro) is encoded by CCA, CCC, CCG or  
CCT;  
10 Glutamine (Gln) is encoded by CAA or CAG;  
Arginine (Arg) is encoded by AGA, AGG, CGA, CGC,  
CGG or CGT;  
Serine (Ser) is encoded by AGC, AGT, TCA, TCC,  
TCG or TCT;  
15 Threonine (Thr) is encoded by ACA, ACC, ACG or  
ACT;  
Valine (Val) is encoded by GTA, GTC, GTG or GTT;  
Tryptophan (Trp) is encoded by TGG; and  
Tyrosine (Tyr) is encoded by TAC or TAT.  
20  
It is to be recognized that according to the present invention, when a cDNA is claimed as described above, it is understood that what is claimed are both the sense strand, the anti-sense strand, and the DNA as  
25 double-stranded having both the sense and anti-sense strand annealed together by their respective hydrogen bonds. Also claimed is the messenger RNA (mRNA) which encodes the polypeptides of the present invention, and which mRNA is encoded by the above-described cDNA. A  
30 messenger RNA (mRNA) will encode a polypeptide using the same codons as those defined above, with the exception that each thymine nucleotide (T) is replaced by a uracil nucleotide (U).  
35 In general, a DNA sequence encoding a Zcyt010 polypeptide is operably linked to other genetic elements required for its expression, generally including a

transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will 5 recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter 10 of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

To direct a Zcyt010 polypeptide into the 15 secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of the protein, or may be derived from another secreted protein (e.g., t- 20 PA) or synthesized *de novo*. The secretory signal sequence is joined to the Zcyt010 DNA sequence in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of interest, although certain signal sequences may be 25 positioned elsewhere in the DNA sequence of interest (see, e.g., Welch *et al.*, U.S. Patent No. 5,037,743; Holland *et al.*, U.S. Patent No. 5,143,830).

Methods for introducing exogenous DNA into mammalian 30 host cells include calcium phosphate-mediated transfection, Wigler *et al.*, *Cell* 14:725 (1978); Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456 (1973), electroporation, Neumann *et al.*, *EMBO J.* 1:841-845 (1982), DEAE-dextran 35 mediated transfection, Ausubel *et al.*, eds., *Current Protocols in Molecular Biology*, (John Wiley and Sons, Inc., NY, 1987), and liposome-mediated transfection,

Hawley-Nelson et al., *Focus* 15:73 (1993); Ciccarone et al., *Focus* 15:80 (1993). The production of recombinant polypeptides in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339;

5 Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134. Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293

10 [ATCC No. CRL 1573; Graham et al., *J. Gen. Virol.* 36:59-72(1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville,

15 Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and

20 4,601,978 and the adenovirus major late promoter.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin.

25 Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by

30 culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high

35

levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, 5 multi-drug resistance, puromycin acetyltransferase) can also be used. Alternative markers that introduce an altered phenotype, such as green fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase may be used to sort 10 transfected cells from untransfected cells by such means as FACS sorting or magnetic bead separation technology.

Other higher eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian 15 cells. Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al., U.S. Patent No. 4,775,624; and WIPO publication WO 94/06463. The use of *Agrobacterium rhizogenes* as a vector for expressing 20 genes in plant cells has been reviewed by Sinkar et al., *J. Biosci. (Bangalore)* 11:47-58 (1987). Insect cells can be infected with recombinant baculovirus, commonly derived from *Autographa californica nuclear polyhedrosis virus* (AcNPV). See, King, L.A. and Possee, R.D., *The 25 Baculovirus Expression System: A Laboratory Guide* (Chapman & Hall, London); O'Reilly, D.R. et al., *Baculovirus Expression Vectors: A Laboratory Manual* (University Press., New York, Oxford, 1994); and, Richardson, C. D., Ed., *Baculovirus Expression Protocols*. 30 *Methods in Molecular Biology*, (Humana Press, Totowa, NJ, 1995). A second method of making recombinant Zcyt010 baculovirus utilizes a transposon-based system described by Luckow, V.A, et al., *J Virol* 67:4566-79 1993). This system, which utilizes transfer vectors, is sold in the 35 *Bac-to-Bac™* kit (Life Technologies, Rockville, MD). This

system utilizes a transfer vector, pFastBac1™ (Life Technologies) containing a Tn7 transposon to move the DNA encoding the Zcyt010 polypeptide into a baculovirus genome maintained in *E. coli* as a large plasmid called a

5 "bacmid." See, Hill-Perkins, M.S. and Possee, R.D., *J Gen Virol* 71:971-6, (1990); Bonning, B.C. et al., *J Gen Virol* 75:1551-6 (1994); and, Chazenbalk, G.D., and Rapoport, B., *J Biol Chem* 270:1543-9 (1995). In addition, transfer vectors can include an in-frame fusion with DNA encoding

10 an epitope tag at the C- or N-terminus of the expressed Zcyt010 polypeptide, for example, a Glu-Glu epitope tag, Grussenmeyer, T. et al., *Proc. Natl. Acad. Sci.* 82:7952-4 (1985). Using a technique known in the art, a transfer vector containing Zcyt010 is transformed into *E. Coli*, and

15 screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect *Spodoptera frugiperda* cells, e.g. Sf9 cells. Recombinant

20 virus that expresses Zcyt010 is subsequently produced. Recombinant viral stocks are made by methods commonly used the art.

The recombinant virus is used to infect host cells, typically a cell line derived from the fall armyworm, *Spodoptera frugiperda*. See, in general, Glick and Pasternak, *Molecular Biotechnology: Principles and Applications of Recombinant DNA*, ASM Press, Washington, D.C. (1994). Another suitable cell line is the High FiveO™ cell line (Invitrogen) derived from *Trichoplusia ni* (U.S. Patent No.5,300,435). Commercially available serum-free media are used to grow and maintain the cells. Suitable media are Sf900 II™ (Life Technologies) or ESF 921™ (Expression Systems) for the Sf9 cells; and Ex-  
35 cellO405™ (JRH Biosciences, Lenexa, KS) or Express FiveO™

(Life Technologies) for the *T. ni* cells. The cells are grown up from an inoculation density of approximately  $2-5 \times 10^5$  cells to a density of  $1-2 \times 10^6$  cells at which time a recombinant viral stock is added at a multiplicity of 5 infection (MOI) of 0.1 to 10, more typically near 3. Procedures used are generally described in available laboratory manuals (King, L. A. and Possee, R.D., *ibid.*; O'Reilly, D.R. et al., *ibid.*; Richardson, C. D., *ibid.*). Subsequent purification of the Zcyt010 polypeptide from 10 the supernatant can be achieved using methods described herein.

Fungal cells, including yeast cells, and particularly cells of the genus *Saccharomyces*, can also be 15 used within the present invention, such as for producing protein fragments or polypeptide fusions. Methods for transforming yeast cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et 20 al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability 25 to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in yeast is the *POT1* vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media.

30 Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092 and alcohol dehydrogenase genes. See also U.S. 35 Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*,

*Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guillermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., *J. Gen. Microbiol.*

- 5 132:3459-3465 (1986) and Cregg, U.S. Patent No. 4,882,279. Aspergillus cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for  
10 transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

The use of *Pichia methanolica* as host for the production of recombinant proteins is disclosed in WIPO Publications WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in transforming *P. methanolica* will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in *P. methanolica*, it is preferred that the promoter and terminator in the plasmid be that of a *P. methanolica* gene, such as a *P. methanolica* alcohol utilization gene (AUG1 or AUG2). Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. To facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment of the plasmid flanked at both ends by host DNA sequences. A preferred selectable marker for use in  
30 *Pichia methanolica* is a *P. methanolica* ADE2 gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), which allows ade2 host cells to grow in the absence of adenine. For large-scale, industrial processes where it is desirable to minimize the use of methanol, it  
35 is preferred to use host cells in which both methanol utilization genes (AUG1 and AUG2) are deleted. For production of secreted proteins, host cells deficient in

vacuolar protease genes (*PEP4* and *PRB1*) are preferred. Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into *P. methanolica* cells. It is preferred to 5 transform *P. methanolica* cells by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant ( $\tau$ ) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.

10

Prokaryotic host cells, including strains of the bacteria *Escherichia coli*, *Bacillus* and other genera are also useful host cells within the present invention. Techniques for transforming these hosts and expressing 15 foreign DNA sequences cloned therein are well known in the art (see, e.g., Sambrook et al., *ibid.*). When expressing a ZcytO10 polypeptide in bacteria such as *E. coli*, the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic 20 space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea. The denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by 25 dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the latter case, the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the 30 cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.

35

Transformed or transfected host cells are cultured according to conventional procedures in a culture

medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell. *P. methanolica* cells are cultured in a medium comprising adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C. Liquid cultures are provided with sufficient aeration by conventional means, such as shaking of small flasks or sparging of fermentors. A preferred culture medium for *P. methanolica* is YEPD (2% D-glucose, 2% Bacto™ Peptone (Difco Laboratories, Detroit, MI), 1% Bacto™ yeast extract (Difco Laboratories), 0.004% adenine and 0.006% L-leucine).

Within one aspect of the present invention, a novel protein is produced by a cultured cell, and the cell is used to screen for a receptor or receptors for the protein, including the natural receptor, as well as agonists and antagonists of the natural ligand.

#### 30 PROTEIN ISOLATION:

It is preferred to purify the polypeptides of the present invention to ≥80% purity, more preferably to ≥90% purity, even more preferably ≥95% purity, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins

and nucleic acids, and free of infectious and pyrogenic agents. Preferably, a purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin.

5

Expressed recombinant polypeptides (or chimeric polypeptides) can be purified using fractionation and/or conventional purification methods and media. Ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples. Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable anion exchange media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred, with DEAE Fast-Flow Sepharose (Pharmacia, Piscataway, NJ) being particularly preferred. Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties. Examples of coupling chemistries include cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries. These and other solid media are well known

and widely used in the art, and are available from commercial suppliers. Methods for binding receptor polypeptides to support media are well known in the art. Selection of a particular method is a matter of routine 5 design and is determined in part by the properties of the chosen support. See, for example, *Affinity Chromatography: Principles & Methods* (Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988).

10 The polypeptides of the present invention can be isolated by exploitation of their properties. For example, immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich proteins. Briefly, a gel is first charged with divalent 15 metal ions to form a chelate (E. Sulkowski, *Trends in Biochem.* 3:1-7 (1985)). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong 20 chelating agents. Other methods of purification include purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography (*Methods in Enzymol.*, Vol. 182, "Guide to Protein Purification", M. Deutscher, (ed.), pp. 529-539 (Acad. Press, San Diego, 25 1990). Alternatively, a fusion of the polypeptide of interest and an affinity tag (e.g., polyhistidine, maltose-binding protein, an immunoglobulin domain) may be constructed to facilitate purification.

30

Uses

The polypeptide of the present invention has the structural characteristics of a four-helix bundle cytokine. A protein is generally characterized as a 35 cytokine by virtue of its solubility and ability to act via cell surface receptors to signal and modulate cell proliferation. Cytokines fall into several tertiary

- structural fold classes, including cysteine-rich dimers (e.g., insulin, PDGF), beta-trefoil folds (e.g., FGF, IL-1), and all-alpha four helix bundles. The latter are characterized by four helices, labeled A,B,C and D, in a unique up-up-down-down topology, where two overhand loops link helices A and B and helices C and D. See, for example, Manavalan *et al.*, *Journal of Protein Chemistry* 11(3): 321-31, (1992). The four-helix bundle cytokines are sometimes further subdivided into short chain (e.g., IL-4, IL-2, GM-CSF) and long chain (e.g., TPO, growth hormone, leptin, IL-10), where the latter generally display longer A and D helices and overhand loops. Henceforth we shall use the term "cytokine" synonymously with "four-helix bundle cytokine". Helix A of Zcyt010 includes amino acid residue 35, an isoleucine, through amino acid residue 49, an isoleucine, also defined by SEQ ID NO:14; helix B includes amino acid 91, a leucine, through amino acid 105, a threonine, also defined by SEQ ID NO:15; helix C includes amino acid residue 112, a 20 leucine, through amino acid residue 126, a cysteine, also defined by SEQ ID NO:16; helix D includes amino acid residue 158, a valine, through amino acid residue 172, a methionine, also defined by SEQ ID NO:17.
- Human Zcyt010 has an intramolecular disulfide bond between Cys33 and Cys126. The other four cysteines, Cys80, Cys132, Cys81 and Cys134 are predicted to form two intramolecular disulfide bonds in the arrangement Cys80-Cys132 and Cys81-Cys134. Residues that are predicted to be crucial for the structural stability of Zcyt010 include Cys33, Cys126, Cys80, Cys132, Cys81 and Cys134. Mutation of any one of these residues to any other residue is expected to inactivate the function of Zcyt010.
- The structural stability of Zcyt010 is also dependent on the maintenance of a buried hydrophobic face on the four alpha helices. Residues Ile42, Phe46, Ile49, Leu91,

Val94, Phe95, Tyr98, Leu112, Phe116, Ile119, Leu123, Val158, Leu162, Leu165, Leu168, Leu169 and Met172 are predicted to be buried in the core of the protein and if they are changed, the substituted amino acid residue must 5 be a hydrophobic amino acid.

Residues expected to be involved in binding of Zcyto10 to a cell surface receptor include Asp57, on the overhand loop between helix A and B, and Lys160 and 10 Glu164, charged residues predicted to be exposed on the surface of helix D. On the surface of the protein, on the loop AB and helix D areas, is a hydrophobic surface patch comprising residues Ile62, Leu71, Ile167, and Trp171. These residues may interact with a hydrophobic surface 15 patch on a cell surface receptor.

The human Zcyto10 polypeptide of the present invention has about a 28% identity to interleukin-10 (IL-10). Mouse Zcyto10 polypeptide has approximately 24% 20 identity to human IL-10, and about 27% identity to mouse IL-10. Human Zcyto10 polypeptide has approximately 76% identity with mouse Zcyto10 polypeptide.

Helix A of mouse Zcyto10 includes amino acid residue 25 35, an isoleucine, through amino acid residue 49, an arginine, of SEQ ID NO: 19, also defined by SEQ ID NO:21. Helix B of mouse Zcyto10 includes amino acid residue 91, a leucine, through amino acid residue 105, a threonine, of SEQ ID NO: 19, also defined by SEQ ID NO:22. Helix C of 30 mouse Zcyto10 includes amino acid residue 112, a leucine, through amino acid residue 126, a cysteine, of SEQ ID NO: 19, also defined by SEQ ID NO:23. Helix D of mouse Zcyto10 includes amino acid residue 158, a valine, through amino acid residue 172, a methionine, of SEQ ID NO: 19, also 35 defined by SEQ ID NO:24.

IL-10 is a cytokine that inhibits production of other cytokines, induces proliferation and differentiation of activated B lymphocytes, inhibits HIV-1 replication and exhibits antagonistic effects on gamma interferon. IL-10 appears to exist as a dimer formed from two alpha-helical polypeptide regions related by a 180° rotation. See, for example, Zdanov et al., *Structure*: 3(6): 591-601 (1996). IL-10 has been reported to be a product of activated Th2 T-cells, B-cells, keratinocytes and monocytes/macrophages that is capable of modulating a Th1 T-cell response. Such modulation may be accomplished by inhibiting cytokine synthesis by Th1 T-cells. See, for example, Hus et al., *Int. Immunol.* 4: 563 (1992) and D'Andrea et al., *J. Exp. Med.* 178: 1042 (1992). IL-10 has also been reported to inhibit cytokine synthesis by natural killer cells and monocytes/macrophages. See, for example, Hus et al. cited above and Fiorentino et al., *J. Immunol.* 146: 3444 (1991). In addition, IL-10 has been found to have a protective effect with respect to insulin dependent diabetes mellitus.

In analysis of the tissue distribution of the mRNA corresponding to this novel DNA, a single transcript was observed at approximately 1.2 kb. Using Clontech Multiple 25 Tissue Northerns, the human transcript was apparent in trachea, placenta, testis, skin, salivary gland, prostate, thyroid with less expression observed in stomach and pancreas. Zcyt010 was expressed in the following mouse tissues: kidney, skeletal muscle, salivary gland, liver 30 and skin.

The tissue specificity of Zcyt010 expression suggests that Zcyt010 may be a growth and/or maintenance 35 factor in the trachea and salivary glands, stomach, pancreas and muscle; and may be important in local immune responses. Also, the Zcyt010 gene's location on chromosome

1q32.2 indicates that Zcyt010 is a growth/differentiation factor or important in regulating the immune response as IL-10.

5 The present invention also provides reagents which will find use in diagnostic applications. A probe comprising the Zcyt010 DNA or RNA or a subsequence thereof can be used to determine if the Zcyt010 gene is present on chromosome 1 or if a mutation has occurred.

10

The present invention also provides reagents with significant therapeutic value. The Zcyt010 polypeptide (naturally occurring or recombinant), fragments thereof, antibodies and anti-idiotypic 15 antibodies thereto, along with compounds identified as having binding affinity to the Zcyt010 polypeptide, should be useful in the treatment of conditions associated with abnormal physiology or development, including abnormal proliferation, e.g., cancerous conditions, or degenerative 20 conditions or altered immunity.

Antibodies to the Zcyt010 polypeptide can be purified and then administered to a patient. These reagents can be combined for therapeutic use with 25 additional active or inert ingredients, e.g., in pharmaceutically acceptable carriers or diluents along with physiologically innocuous stabilizers and excipients. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or 30 storage in stabilized aqueous preparations. This invention also contemplates use of antibodies, binding fragments thereof or single-chain antibodies of the antibodies including forms which are not complement binding.

35 The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site,

physiological state of the patient, and other medications administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful  
5 for *in vivo* administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Methods for administration include oral, intravenous, peritoneal, intramuscular, transdermal or  
10 administration into the lung or trachea in spray form by means or a nebulizer or atomizer. Pharmaceutically acceptable carriers will include water, saline, buffers to name just a few. Dosage ranges would ordinarily be expected from 1 $\mu$ g to 1000 $\mu$ g per kilogram of body weight  
15 per day. However, the doses may be higher or lower as can be determined by a medical doctor with ordinary skill in the art. For a complete discussion of drug formulations and dosage ranges see *Remington's Pharmaceutical Sciences*, 18<sup>th</sup> Ed., (Mack Publishing Co., Easton, Penn.,  
20 1996), and *Goodman and Gilman's: The Pharmacological Bases of Therapeutics*, 9<sup>th</sup> Ed. (Pergamon Press 1996).

Nucleic Acid-based Therapeutic Treatment

25 If a mammal has a mutated or lacks a Zcyt010 gene, the Zcyt010 gene can be introduced into the cells of the mammal. In one embodiment, a gene encoding a Zcyt010 polypeptide is introduced *in vivo* in a viral vector. Such vectors include an attenuated or defective DNA virus, such  
30 as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. A defective virus is not infective  
35 after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect

other cells. Examples of particular vectors include, but are not limited to, a defective herpes virus 1 (HSV1) vector [Kaplitt et al., *Molec. Cell. Neurosci.*, 2 :320-330 (1991)], an attenuated adenovirus vector, such as the 5 vector described by Stratford-Perricaudet et al., *J. Clin. Invest.*, 90 :626-630 (1992), and a defective adeno-associated virus vector [Samulski et al., *J. Virol.*, 61:3096-3101 (1987); Samulski et al. *J. Virol.*, 63:3822-3828 (1989)].

10

In another embodiment, the gene can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al., *Cell*, 33:153 (1983); Temin et al., U.S. Patent No. 4,650,764; Temin et 15 al., U.S. Patent No. 4,980,289; Markowitz et al., *J. Virol.*, 62:1120 (1988); Temin et al., U.S. Patent No. 5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995 by Dougherty et al.; and *Blood*, 82:845 (1993). Alternatively, the vector can be 20 introduced by lipofection *in vivo* using liposomes.

Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker [Felgner et al., *Proc. Natl. Acad. Sci. USA*, 84:7413-7417 (1987); see Mackey et al., *Proc. Natl. Acad. Sci. USA*, 25 85:8027-8031 (1988)]. The use of lipofection to introduce exogenous genes into specific organs *in vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. It is clear that directing transfection to particular cells represents 30 one area of benefit. It is clear that directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, and brain. Lipids may be chemically coupled to other molecules 35 for the purpose of targeting. Targeted peptides, e.g., hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to

liposomes chemically. These liposomes can also be administered in spray form into the lung or trachea by means of an atomizer or nebulizer.

5 It is possible to remove the cells from the body and introduce the vector as a naked DNA plasmid and then re-implant the transformed cells into the body. Naked DNA vector for gene therapy can be introduced into the desired host cells by methods known in the art, e.g.,  
10 transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter [see, e.g., Wu et al., *J. Biol. Chem.*, 267:963-967 (1992); Wu et al., *J. Biol. Chem.*, 263:14621-  
15 14624 (1988)].

Zcyto10 polypeptides can also be used to prepare antibodies that specifically bind to Zcyto10 polypeptides. These antibodies can then be used to manufacture anti-  
20 idiotypic antibodies. As used herein, the term "antibodies" includes polyclonal antibodies, monoclonal antibodies, antigen-binding fragments thereof such as F(ab')<sub>2</sub> and Fab fragments, and the like, including genetically engineered antibodies. Antibodies are defined  
25 to be specifically binding if they bind to a Zcyto10 polypeptide with a K<sub>a</sub> of greater than or equal to 10<sup>7</sup>/M. The affinity of a monoclonal antibody can be readily determined by one of ordinary skill in the art (see, for example, Scatchard, *ibid.*).  
30

Methods for preparing polyclonal and monoclonal antibodies are well known in the art (see for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition (Cold Spring Harbor, NY, 1989); and Hurrell, J. G. R., Ed., *Monoclonal Hybridoma Antibodies: Techniques and Applications* (CRC Press, Inc., Boca Raton, FL, 1982), which are incorporated herein by reference).

As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats. The immunogenicity of a Zcyto10 polypeptide may be increased through the use of an adjuvant such as Freund's complete or incomplete adjuvant. A variety of assays known to those skilled in the art can be utilized to detect antibodies which specifically bind to Zcyto10 polypeptides. Exemplary assays are described in detail in *Antibodies: A Laboratory Manual*, Harlow and Lane (Eds.), (Cold Spring Harbor Laboratory Press, 1988). Representative examples of such assays include: concurrent immunoelectrophoresis, radio-immunoassays, radio-immunoprecipitations, enzyme-linked immunosorbent assays (ELISA), dot blot assays, inhibition or competition assays, and sandwich assays.

Antibodies to Zcyto10 are may be used for tagging cells that express the protein, for affinity purification, within diagnostic assays for determining circulating levels of soluble protein polypeptides, and as antagonists to block ligand binding and signal transduction *in vitro* and *in vivo*.

25

Within another aspect of the present invention there is provided a pharmaceutical composition comprising purified Zcyto10 polypeptide in combination with a pharmaceutically acceptable vehicle. Such compositions may be useful for modulating of cell proliferation, cell differentiation or cytokine production in the prevention or treatment of conditions characterized by improper cell proliferation, cell differentiation or cytokine production, as are further discussed herein. Moreover, Zcyto10 polypeptides of the present invention may be used in trachea-specific or tracheobronchial-specific

applications, such as in the maintenance or wound repair of the tracheobronchial epithelium or cells underlying the same, in regulating mucous production or mucociliary clearance of debris or in treatment of asthma, bronchitis 5 or other diseases of the tracheobronchial tract. It is expected that Zcyto10 polypeptide would be administered at a dose ranging between the same doses used for Zcyto10-Fc construct to doses 100-fold higher, depending upon the stability of Zcyto10 polypeptide. Therapeutic doses of 10 Zcyto10 would range from 5 to 5000 µg/kg/day.

The Zcyto10 polypeptide of the present invention is expressed highly in salivary gland and trachea and has been found in saliva by Western blot analysis. The 15 salivary glands synthesize and secrete a number of proteins having diverse biological functions. Such proteins facilitate lubrication of the oral cavity (e.g., mucins and proline-rich proteins), remineralization (e.g., statherin and ionic proline-rich proteins) and digestion 20 (e.g., amylase, lipase and proteases) and provide antimicrobial (e.g., proline-rich proteins, lysozyme, histatins and lactoperoxidase) and mucosal integrity maintenance (e.g., mucins) capabilities. In addition, saliva is a rich source of growth factors synthesized by 25 the salivary glands. For example, saliva is known to contain epidermal growth factor (EGF), nerve growth factor (NGF), transforming growth factor-alpha (TGF- $\alpha$ ), transforming growth factor-beta (TGF- $\beta$ ), insulin, insulin-like growth factors I and II (IGF-I and IGF-II) and. 30 fibroblast growth factor (FGF). See, for example, Zelles et al., *J. Dental. Res.* 74(12): 1826-32, 1995. Synthesis of growth factors by the salivary gland is believed to be androgen-dependent and to be necessary for the health of the oral cavity and gastrointestinal tract.

- Thus, Zcyto10 polypeptides, agonists or antagonists thereof may be therapeutically useful in the regeneration of the gastrointestinal tract or oral cavity. To verify this presence of this capability in Zcyto10 polypeptides,
- 5      agonists or antagonists of the present invention, such Zcyto10 polypeptides, agonists or antagonists are evaluated with respect to their ability to break down starch according to procedures known in the art. Zcyto10 polypeptides, agonists or antagonists thereof may be
- 10     useful in the treatment of asthma and other diseases of the tracheobronchial tract, such as bronchitis and the like, by intervention in the cross-regulation of *Th1* and *Th2* lymphocytes, regulation of growth, differentiation and cytokine production of other inflammatory cellular
- 15     mediators, such as eosinophils, mast cells, basophils, neutrophils and macrophages. Zcyto10 polypeptides, agonists or antagonists thereof may also modulate muscle tone in the tracheobronchial tract.
- 20     Zcyto10 polypeptides can also be used to treat a number of skin conditions either systemically or locally when placed in an ointment or cream, for example eczema, psoriasis or dry skin conditions in general or as related skin attentions. Also the Zcyto10 polypeptide can be
- 25     directly injected into muscle to treat muscle atrophy in the elderly, the sick or the bed-ridden.
- Radiation hybrid mapping is a somatic cell genetic technique developed for constructing high-resolution,
- 30     contiguous maps of mammalian chromosomes [Cox et al., *Science* 250:245-250 (1990)]. Partial or full knowledge of a gene's sequence allows the designing of PCR primers suitable for use with chromosomal radiation hybrid mapping panels. Commercially available radiation hybrid mapping
- 35     panels which cover the entire human genome, such as the Stanford G3 RH Panel and the GeneBridge 4 RH Panel (Research Genetics, Inc., Huntsville, AL), are available.

These panels enable rapid, PCR based, chromosomal localizations and ordering of genes, sequence-tagged sites (STSs), and other nonpolymorphic- and polymorphic markers within a region of interest. This includes establishing

5 directly proportional physical distances between newly discovered genes of interest and previously mapped markers. The precise knowledge of a gene's position can be useful in a number of ways including: 1) determining if a sequence is part of an existing contig and obtaining

10 additional surrounding genetic sequences in various forms such as YAC-, BAC- or cDNA clones, 2) providing a possible candidate gene for an inheritable disease which shows linkage to the same chromosomal region, and 3) for cross-referencing model organisms such as mouse which may

15 be beneficial in helping to determine what function a particular gene might have.

The results showed that the Zcyt010 gene maps 889.26 cR\_3000 from the top of the human chromosome 1 linkage

20 group on the WICGR radiation hybrid map. Proximal and distal framework markers were D1S504 and WI-9641 (D1S2427), respectively. The use of the surrounding markers positions the Zcyt010 gene in the 1q32.2 region on the integrated LDB chromosome 1 map (The Genetic Location

25 Database, University of Southampton, WWW server: [http://cedar.genetics.soton.ac.uk/public\\_html/](http://cedar.genetics.soton.ac.uk/public_html/)). Numerous genes have been mapped to the 1q32.2 region of chromosome 1. In particular, mutations in this region have been found to result in van der Woude syndrome, associated with

30 malformation of the lower lip that is sometimes associated with cleft palate. Thus, the Zcyt010 gene, which is expressed in the salivary gland, may be used in gene therapy of this syndrome. If a mammal has a mutated or lacks a Zcyt010 gene, the Zcyt010 gene can be introduced

35 into the cells of the mammal.

Another aspect of the present invention involves antisense polynucleotide compositions that are complementary to a segment of the polynucleotide set forth in SEQ ID NOS: 1, 3 18 and 33. Such synthetic antisense oligonucleotides are designed to bind to mRNA encoding Zcyt010 polypeptides and inhibit translation of such mRNA. Such antisense oligonucleotides are useful to inhibit expression of Zcyt010 polypeptide-encoding genes in cell culture or in a subject.

10

The present invention also provides reagents which will find use in diagnostic applications. For example, the Zcyt010 gene, a probe comprising Zcyt010 DNA or RNA or a subsequence thereof can be used to determine if the Zcyt010 gene is present on chromosome 1 or if a mutation has occurred. Detectable chromosomal aberrations at the Zcyt010 gene locus include but are not limited to aneuploidy, gene copy number changes, insertions, deletions, restriction site changes and rearrangements. Such aberrations can be detected using polynucleotides of the present invention by employing molecular genetic techniques, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, and other genetic linkage analysis techniques known in the art [Sambrook et al., *ibid.*; Ausubel, et. al., *ibid.*; Marian, A.J., *Chest*, 108: 255-265, (1995)].

30

Those skilled in the art will recognize that the sequences disclosed in SEQ ID NOS: 2, 4 12, 13, 19, 20, 25, 26, 34 and 35 represent a single alleles of the human and mouse Zcyt010 genes and polypeptides, and that allelic variation and alternative splicing are expected to occur. Allelic variants can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Allelic variants of the DNA sequence shown in

SEQ ID NOS: 1, 3, 18 and 33 including those containing silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention.

5

The sequence of Zcyt010 has 7 message instability motifs in the 3' untranslated region at positions 706, 813, 855 and 906 of SEQ ID NO:1. Treatment of cells expressing Zcyt010 with cycloheximide can alleviate this message instability. See Shaw, G. et. al., *Cell* 46: 659-667 (1986). Furthermore, the AT rich 3' untranslated region can be genetically altered or removed to further promote message stability.

15

#### USE OF ZCYTO10 TO PROMOTE WOUND HEALING

The data of Example 4 shows that Zcyt010 plays a role in wound healing. Thus, Zcyt010 can be applied to a wound or a burn to promote wound healing. Zcyt010 may be administered systemically in a dosage of from 1 to 100 µg per kilogram weight of the individual. Zcyt010 may also be applied to a wound by means of a salve or ointment which contains from 1mg to 1mg of Zcyt010 to gram of salve or ointment. See *Remington's Pharmaceutical Sciences*, 18<sup>th</sup> Ed., (Mack Publishing Co., Easton, Penn., 1996). Zcyt010 should be placed on a cleaned wound on a daily basis until the wound has healed.

30

#### USE OF ZCYTO10 TO INCREASE PLATELET COUNT

As can be seen below in Example 7, we have discovered that Zcyt010 can be used to increase platelet count. This is especially important to cancer patients who experience thrombocytopenia due to chemotherapy or radiation therapy. The Zcyt010 can be administered therapeutically in with a pharmaceutically acceptable carrier.

The invention is further illustrated by the following  
5 non-limiting examples.

Example 1.

Cloning of Zcyt010

10 The full length sequence of zcyt010x1 (the longer form) and zcyt010x2 (the shorter form) was elucidated by using 3' RACE® and submitting two fragments generated to sequencing (SEQ ID NO:10 and SEQ ID NO:11), then artificially splicing together by computer the est  
15 sequence shown in SEQ ID NO:5 with the overlapping sequence from the two 3' race fragments.

An oligo, zc15907 (SEQ ID NO: 6), was designed to the area just upstream (5') of the putative methionine for zcyt010. Further downstream, another oligo, zc15906 (SEQ 20 ID NO: 7), was designed to the area just upstream of the signal sequence cleavage site. These oligos were used in 3' RACE reactions on human trachea marathon cDNA. ZC15907 was used in the primary 3' race reaction and zc15906 was used in the nested 3' race reaction. The MARATHON cDNA was 25 made using the Marathon cDNA Amplification Kit (Clontech, Palo Alto, CA) according to the manufacturer's instructions, starting with human trachea mRNA purchased from Clontech.

30 The PCR reactions were run according to the manufacturer's instructions in the Marathon cDNA Amplification Kit with some modification in the thermal cycling parameters. The cycling parameters used in the primary PCR reaction were:

94°C 1 min 30sec 1x

94°C 15 sec 68°C 1min 30x

72°C 7min 1x

The cycling parameters used in the nested PCR reaction were: 94°C 1 min 30 sec 1x, 94°C 15 sec 68°C 1 min 20 sec,  
5 30X 72°C 7 min 1x

The resulting products were run out on a 1.2% agarose gel (Gibco agarose) and two main bands were seen, approximately 80 bp apart. The bands were cut out and gel purified using QIAEX™ resin (Qiagen) according to the  
10 manufacturer's instructions. These fragments were then subjected to sequencing, allowing the full length sequence of zcyt010 to be discerned.

#### Example 2

15

#### Northern Blot Analysis

Human multiple tissue blots I, II, III, and a RNA Master Dot Blot (Clontech) were probed to determine the tissue distribution of zcyt010. A 45-mer antisense oligo, SEQ ID  
20 NO:9, was designed using the est sequence (SEQ ID NO: 5 bp 100-145) and used for the probe.

15pm of SEQ ID NO: 9 were end labeled with  $^{32}\text{P}$  using T4 polynucleotide kinase (Gibco-BRL). The labeling  
25 reaction contained 2  $\mu\text{l}$  5X forward kinase reaction buffer (Gibco-BRL), 1ul T4 kinase, 15 pm SEQ ID NO:9, 1ul 6000Ci/mmol  $^{32}\text{P}$  gamma-ATP (Amersham) and water to 10ul. The reaction was incubated 30 minutes at 37°C. Unincorporated radioactivity was removed with a NucTrap Probe  
30 Purification Column (Stratagene). Multiple tissue northerns and a human RNA Master Blot (Clontech) were prehybridized at 50°C three hours in 10ml ExpressHyb (Clontech) which contained 1mg of salmon sperm DNA and

0.3mg human cot1 DNA (Gibco-BRL), both of which were boiled 3 minutes, iced 2 minutes and then added to the ExpressHyb. Hybridization was carried out over night at 50 C. Initial wash conditions were as follows: 2X SSC, 0.1%  
5 SDS RT for 40 minutes with several wash solution changes, then 1X SSC, 0.1% SDS at 64°C (Tm-10) for 30 minutes. Filters were then exposed to film two days.

Expression of zcyt010 on the northern blots revealed  
10 about a 1.2kb band in trachea, a faint 1.5kb band in stomach and fainter bands of both sizes in pancreas. The dot blots showed the presence of zcyt010 in trachea, salivary gland, placenta, testis, skin, prostate gland, adrenal gland and thyroid.

15

In the mouse it was found in the kidney, skeletal muscle, salivary gland, liver and skin.

### Example 3

20

#### Chromosomal Assignment and Placement of Zcyt010.

Zcyt010 was mapped to chromosome 1 using the commercially available version of the "Stanford G3 Radiation Hybrid Mapping Panel" (Research Genetics, Inc.,  
25 Huntsville, AL). The "Stanford G3 RH Panel" contains PCRable DNAs from each of 83 radiation hybrid clones of the whole human genome, plus two control DNAs (the RM donor and the A3 recipient). A publicly available WWW server (<http://shgc-www.stanford.edu>) allows chromosomal localization of markers.  
30

For the mapping of Zcyt010 with the "Stanford G3 RH Panel", 20 µl reactions were set up in a PCRable 96-well microtiter plate (Stratagene, La Jolla, CA) and used in a "RoboCycler Gradient 96" thermal cycler (Stratagene). Each of the 85 PCR reactions consisted of 2 µl 10X KlenTaq PCR

reaction buffer (CLONTECH Laboratories, Inc., Palo Alto, CA), 1.6 µl dNTPs mix (2.5 mM each, PERKIN-ELMER, Foster City, CA), 1 µl sense primer, SEQ ID NO: 6, 5' ATT CCT AGC TCC TGT GGT CTC CAG 3', 1 µl antisense primer, (SEQ ID NO: 8) 5' TCC CAA ATT GAG TGT CTT CAG T 3', 2 µl "RediLoad" (Research Genetics, Inc., Huntsville, AL), 0.4 µl 50X Advantage KlenTaq Polymerase Mix (Clontech Laboratories, Inc.), 25 ng of DNA from an individual hybrid clone or control and x µl ddH<sub>2</sub>O for a total volume of 20 µl. The reactions were overlaid with an equal amount of mineral oil and sealed. The PCR cycler conditions were as follows: an initial 1 cycle 5 minute denaturation at 95°C, 35 cycles of a 1 minute denaturation at 95°C, 1 minute annealing at 66°C and 1.5 minute extension at 72°C, followed by a final 1 cycle extension of 7 minutes at 72°C. The reactions were separated by electrophoresis on a 2% agarose gel (Life Technologies, Gaithersburg, MD).

The results showed linkage of Zcyt010 to the framework marker SHGC-36215 with a LOD score of >10 and at a distance of 14.67cR\_10000 from the marker. The use of surrounding markers positions Zcyt010 in the 1q32.2 region on the integrated LDB chromosome 1 map (The Genetic Location Database, University of Southampton, WWW server: [http://cedar.genetics.soton.ac.uk/public\\_html/](http://cedar.genetics.soton.ac.uk/public_html/)).

#### Example 4

##### Use of Zcyt010 to Promote Wound Healing

Normal adult female Balb/C mice were used in the present study. They were housed in animal care facilities with a 12-hour light-dark cycle, given water and laboratory rodent chow *ad libitum* during the study. They were individually caged from the day of surgery.

35

On the day of surgery, the animals were anesthetized with ketamine (Vetalar, Aveco Inc., Ft. Dodge, IA) 104

mg/kg plus Xylazine (Rompun, Mobey Corp., Shawnee, KS) 7 mg/kg in sterile (0.2  $\mu$ -filtered) phosphate buffered saline (PBS) by intraperitoneal injection. The hair on their backs was clipped and the skin depilated with NAIR® (Carter-Wallace, New York, NY), then rinsed with water. 100% aloe vera gel was applied to counteract the alkaline burn from the NAIR® treatment, then the animals were placed on circulating water heating pads until the skin and surrounding fur were dry.

10

The animals were then anesthetized with metofane (Pittman Moore, Mundelein, NJ) and the depilated dorsum wiped with 70% ethanol. Four excisions, each of 0.5-cm square were made through the skin and panniculus carnosus over the paravertebral area at the level of the thoracic-lumbar vertebrae. The wounds and surrounding depilated skin were covered with an adhesive, semipermeable occlusive dressing, BIOCLUSIVE® (Johnson & Johnson, Arlington, TX). The cut edge of the excision was traced through the BIOCLUSIVE® onto an acetate transparency for later assessment of closure parameters.

Control skin and wounded skin at different time points (7 hours, 15 hours and 24 hours) were processed using the Qiagen RNeasy Midi kit. Briefly, skin (control and wounded areas) were weighed and homogenized in appropriate volume of lysis buffer (RLT). The lysates were spun to remove tissue debris and equal volume of 70% ethanol was added to the lysates; mixed well and loaded on column. The samples were spun five minutes and washed once with 3.8 ml of RW1 buffer, then twice with RPE (2.5 ml each). The total RNA's were eluted with RNase-free water. The expression level of the skin samples were measured using real time PCR (Perkin Elmer ABI Prism 7700 Sequence Detector).

The experiment was designed with a non template control, a set of standard and the skin samples. Mouse kidney total RNA was use for the standard curve. Three sets of skin total RNA's (25 ng) were used in this 5 experiment 7 hours (control and wounded); 15hours (control and wounded), 24hours (control and wounded). Each sample was done in triplicate by One Step RT-PCR on the 7700 sequence detector. The in-house forward primer SEQ ID NO:36, reverse primer SEQ ID NO:37, and the Perkin Elmer's 10 TaqMan probe (ZG-7-FAM) were used in the experiment. The condition of the One Step RT-PCR was as follow: (RT step) 48° C for 30 minutes, (40 cycles PCR step) 95° C for 10 minutes, 95° C for 15 second, 60°C for 1 minute.

15 The expression level of cyto10 in the control skin samples at 7 hours and 15 hours were comparable at 2.46 ng/ml and 2.61 ng/ml respectively. From the control skin sample at 24 hours, the expression level of Zcyto10 was zero. The expression level of cyto10 from wounded skin at 20 7 hours was at 5.17 ng/ml ( more than two fold increase compared to that of the control sample). The expression level of cyto10 from wounded skin at 15 hours was at 14.45 ng/ml ( 5.5 fold increase compared to that of the control sample). The expression level of cyto10 from wounded skin 25 at 24 hours was at 5.89 ng/ml. A repeat experiment also included a negative control (yeast tRNA) gave the similar trend and the result of yeast tRNA was near zero. The result suggested that the amplification was real and mouse specific.

30

These data suggest that Zcyto10 plays a role in the repair of wounded because the expression level of Zcyto10 from wounded tissue was up compared to that of the control sample and it increased and decreased after time. Thus, 35 Zcyto10 can be applied to wounds to promote wound healing.

Example 5  
Transgenic Mice

Transgenic mice were produced which expressed Zcyt010  
5 either under the albumin or the metallothioneine promoter.  
At birth, several of the mice had a shiny appearance and  
had limited movement. The skin of these mice was tight and  
wrinkled, several also had a whisker-like hair on the  
lower lip. The nostril and mouth areas, the extremities  
10 and the tail were swollen.

One transgenic mouse, in which the albumin promoter  
was used survived until day three and was severely growth  
retarded. There was no ear development and the development  
15 of the toes was diminished. All animals were sacrificed  
when they were moribund on days 1, 2 or 3. Tails and liver  
samples were collected and they were fixed *in situ* in 10%  
neutral formalin embedded in paraffin, and sectioned at 3  
micrometers and stained with H&E. All mice with this  
20 phenotype were transgenic and had low to high expression  
of Zcyt010.

No significant changes were observed in the majority  
of the tissues except for the skin. The skin of the  
25 zcyt010 expressing pups, particularly those mice which  
had a high expression level of Zcyt010, tended to be  
thicker than the non-expressing pups. The stratum  
granulosum in these pups appeared to be reduced in  
thickness as compared to the non-expressing pups, while  
30 the stratum spinosum was thicker due to increased cell  
layers and/or increased cell diameter.

In addition to the changes in the epidermis, the  
dermis of one mouse having medium expression of Zcyt010  
35 was focally moderately expanded by mucinous material.

Example 6Purification of Zcyt010 from a Cell Culture Medium

5       Zcyt010 produced by CHO cells was isolated from the cell culture medium using a two step method involving a cation exchange chromatography and size exclusion chromatography.

10      A. Cation Exchange Chromatography Step.

Materials Used

15      2.2 cm diameter (D) x 6 cm height (H) column (AMICON) packed with a SP-650M cation exchange resin, which is a TOYOPEARL ion exchange resin having covalently bonded sulfopropyl (SP) groups.

20      Fifteen (15) liters of culture medium from baby hamster kidney (BHK) cells which had been transfected with a Zcyt010 containing plasmid was collected. The pH of the culture medium was adjusted to pH5 with 2N HCl. The above-described packed column was equilibrated with 50 mM sodium acetate, NaAc, pH5.0. The culture medium was loaded onto 25 the column at the rate of 20 column-volumes (cv)/hr at approximately 8 ml/min. When the loading was done the column was washed with 10 cv of 50 mM NaAc, pH5.0. The material in the column was then eluted with 20 cv of NaCl gradient in 50 mM NaAc, pH 5.0. The NaCl gradient ranged 30 from 0 to 0.5 M NaCl. This concentrated the material in the culture medium from 15 liters to 170 ml.

The resultant 170 ml harvest was further concentrated to about 5 ml with a spin 5 thousand cut-off centrifugal 35 concentrator (Millipore, Inc. Bedford, MA).

B. Size Exclusion (S-100) Gel Filtration Step

## Materials Used.

Column 1.6 cm (diameter) X 93 cm (height)  
S-100 gel (Pharmacia, Piscataway, NJ)

5

The 5 ml harvest was then loaded onto the above-described column containing S-100 gel. The column had been equilibrated with 5X phosphate buffered saline to bring the pH of the column to about 7.0. Zcyt010 was isolated from the contaminants by using 1X PBS at a flow rate of 1.5 ml/min. Fractions were collected at 2 ml increments. The Zcyt010 polypeptide came out in fractions 52-64 at about 90 minutes after the elution had been initiated as determined by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis which were stained with Coomassie Blue. The gel revealed one band at the predicted molecular weight of about 14 kDa.

20

Example 7Cloning of Murine Zcyt010

PCR primers 5' MARATHON RACE™ (Clontech, Palo Alto, CA) primer set SEQ ID NO: 38 attached to MARATHON™ AP1 adapter, nested with SEQ ID NO:39 attached to AP2  
25 MARATHON™ adapter, with 3' MARATHON RACE™ primer set SEQ ID NO: 40 attached to MARATHON RACE™ AP1 adapter, nested with SEQ ID NO:41 attached to MARATHON RACE™ AP2 adapter and 5' and 3' race was performed on mouse skin MARATHON RACE™ cDNA. Several fragments were from these reactions  
30 were gel purified and sequenced, allowing the elucidation of the full length coding sequence of the mouse zcyt010, plus some 5' and 3' UTR sequence. Two murine Zcyt010 variants were discovered, namely SEQ ID NOs: 18 and 19 and SEQ ID NOs: 33 and 34. The clones were amplified by PCR  
35 using primers SEQ ID NOs:42 and 43.

Example 8Adenovirus Administration of Zcyt010 to Normal Mice

5       Zcyt010 was administered by adenovirus containing the  
Zcyt010 gene. There were three groups of mice as described  
below. The adenovirus was injected intravenously into  
C57Bl/6 male and female mice. All mice received  
bromodeoxyuridine (BrdU) in their drinking water 3 days  
10 before sacrifice. This allowed for detection of cell  
proliferation by histologic methods. Parameters measured  
included weight change, complete blood counts, serum  
chemistries, histology, organ weights and cell  
proliferation by BrdU.

15

Experimental Design

20       Group 1    Zcyt010X1 (SEQ ID NO:18)/pAC-CMV/Adv  
             $1 \times 10^{11}$  particles/dose  
            (9 females, 9 males sacrificed on day 21)  
            (2 females, 2 males sacrificed on day 11)  
            total number = 22 mice.

25       Group 2    null CMV/Adv control  
             $1 \times 10^{11}$  particles/dose  
            (10 females, 10 males sacrificed on day 21)  
            (2 females, 2 males sacrificed on day 11)  
            total number = 24 mice.

30

Group 3    no treatment  
            (5 females, 5 males)  
            total number = 10.

Results

The most striking effect was a significant increase in platelet count which was observed in male and female 5 mice treated with Zcyt010-adenovirus compared to empty adenovirus control. This was accompanied in male mice by a decrease hematocrit and increased spleen and liver weight. The thymus weight was decreased in males also. In contrast Zcyt010-adenovirus treated female mice showed 10 significantly increased white blood cell counts which were consisted primarily of increased lymphocyte and neutrophil counts compared to the empty virus control.

These results suggest that hematopoiesis is effected 15 by Zcyt010 treatment, but except for the increased platelet count which effected both sexes, other effects are sex specific.

Other effects included the following.  
20 Female glucose levels were lower in treated groups while those of the males showed no significant change.

Blood Urea Nitrogen (BUN) was higher in both male and 25 female treated groups.

Female alkaline phosphatase was higher in the treated group while the males showed no significant change.

30 The platelet counts were higher in both male and female treated groups.

Female total white blood counts (WBC) were higher in the treated groups while the males showed no significant 35 change.

## CLAIMS:

## WHAT IS CLAIMED IS:

1. An isolated polynucleotide which encodes a polypeptide, said polypeptide being at least 90% identical to one or more of the polypeptides selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34 and SEQ ID NO:35.
2. An isolated polynucleotide of claim 1 wherein the polynucleotide encodes a polypeptide containing an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34 and SEQ ID NO:35.
3. An isolated polynucleotide of claim 1 wherein said polynucleotide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:18 and SEQ ID NO:33.
4. A polynucleotide which encodes a polypeptide which has the amino acid sequence of an epitope-bearing portion of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34 and SEQ ID NO:35.
5. The isolated polynucleotide of claim 4 wherein said polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID

NO:24, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32.

6. The isolated polynucleotide of claim 4 wherein said polynucleotide encodes a polypeptide which is at least 80% identical to one or more polypeptides selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34 and SEQ ID NO:35.
7. An isolated polypeptide which is at least 90% identical to one or more polypeptides selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34 and SEQ ID NO:35.
8. An isolated polypeptide of claim 7 wherein said polypeptide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34 and SEQ ID NO:35.
9. A polypeptide which has an amino acid sequence of an epitope-bearing portion of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34 and SEQ ID NO:35.
10. A polypeptide of claim 9 wherein said polypeptide is selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:27, SEQ ID

NO:28, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32.

11. The polypeptide of claim 9 wherein said polypeptide is at least 80% identical to a polypeptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34 and SEQ ID NO:35.
12. An antibody which selectively binds to a polypeptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32.
13. An anti-idiotypic antibody which binds to an antibody of claim 12.

## SEQUENCE LISTING

<110> ZymoGenetics, Inc.

<120> MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10

<130> 97-72PC

<160> 43

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 926

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (45)...(572)

<400> 1

ctttgaattc ctagtcctg tggcttccag atttcaggcc taag atg aaa gcc tct  
Met Lys Ala Ser  
1

agt ctt gcc ttc agc ctt ctc tct gct gcg ttt tat ctc cta tgg act  
Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr Leu Leu Trp Thr  
5 10 15 20  
104

cct tcc act gga ctg aag aca ctc aat ttg gga agc tgt gtg atc gcc  
Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala  
25 30 35  
152

aca aac ctt cag gaa ata cga aat gga ttt tct gac ata cgg ggc agt  
Thr Asn Leu Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser  
40 45 50  
200

gtg caa gcc aaa gat gga aac att gac atc aga atc tta agg agg act  
Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr  
55 60 65  
248

gag tct ttg caa gac aca aag cct gcg aat cga tgc tgc ctc ctg cgc  
Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg  
70 75 80  
296

cat ttg cta aga ctc tat ctg gac agg gta ttt aaa aac tac cag acc		344
His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr		
85	90	95
		100
cct gac cat tat act ctc cg <sup>g</sup> aag atc agc agc ctc gcc aat tcc ttt		392
Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe		
105	110	115
ctt acc atc aag aag gac ctc cg <sup>g</sup> ctc tgt cat gcc cac atg aca tgc		440
Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His Ala His Met Thr Cys		
120	125	130
cat tgt ggg gag gaa gca atg aag aaa tac agc cag att ctg agt cac		488
His Cys Gly Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His		
135	140	145
ttt gaa aag ctg gaa cct cag gca gca gtt gtg aag gct ttg ggg gaa		536
Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu		
150	155	160
cta gac att ctt ctg caa tgg atg gag gag aca gaa taggaggaaa		582
Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu		
165	170	175
gtgatgctgc tgctaagaat attcgaggc aagagctcca gtcttcaata cctgcagagg		642
aggcatgacc ccaaaccacc atctcttac tgtactagtc ttgtgctggcacagtgtat		702
cttatttatg cattacttgc ttcccttgcattgtcttt atgcattcccc aatcttaatt		762
gagaccatac ttgtataaga ttttgtaat atctttctgc tattggatat atttatttagt		822
taatatattt atttatttt tgctattaat gtatttaatt ttttacttgg gcatgaaact		882
ttaaaaaaaa ttcacaagat tatattata acctgactag agca		926

&lt;210&gt; 2

&lt;211&gt; 176

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Lys Ala Ser Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr			
1	5	10	15
Leu Leu Trp Thr Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser			
20	25	30	
Cys Val Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp			
35	40	45	
Ile Arg Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile			

50	55	60
Leu Arg Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys		
65	70	75
Cys Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys		
85	90	95
Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu		
100	105	110
Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His Ala		
115	120	125
His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln		
130	135	140
Ile Leu Ser His Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys		
145	150	155
Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu		
165	170	175

&lt;210&gt; 3

&lt;211&gt; 793

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (45)...(497)

&lt;400&gt; 3

ctttgaattc cttagtcctg tggctccat atttcaggcc taag atg aaa gcc tct	56
Met Lys Ala Ser	
1	

agt ctt gcc ttc agc ctt ctc tct gct gcg ttt tat ctc cta tgg act	104		
Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr Leu Leu Trp Thr			
5	10	15	20

cct tcc act gga ctg aag aca ctc aat ttg gga agc tgt gtg atc gcc	152	
Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala		
25	30	35

aca aac ctt cag gaa ata cga aat gga ttt tct gac ata cgg ggc agt	200	
Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser		
40	45	50

gtg caa gcc aaa gat gga aac att gac atc aga atc tta agg agg act	248	
Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr		
55	60	65

gag tct ttg caa gac aca aag cct gcg aat cga tgc tgc ctc ctg cgc Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg 70 75 80	296
cat ttg cta aga ctc tat ctg gac agg gta ttt aaa aac tac cag acc His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr 85 90 95 100	344
cct gac cat tat act ctc cg <sup>g</sup> aag atc agc agc ctc gcc aat tcc ttt Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe 105 110 115	392
ctt acc atc aag aag gac ctc cg <sup>g</sup> ctc tgt ctg gaa cct cag gca gca Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys Leu Glu Pro Gln Ala Ala 120 125 130	440
gtt gtg aag gct ttg ggg gaa cta gac att ctt ctg caa tgg atg gag Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu 135 140 145	488
gag aca gaa taggaggaaa gtgatgctgc tgctaagaat attcgaggc Glu Thr Glu 150	537
aagagctcca gtcttcaata cctgcagagg aggcattgacc ccaaaccacc atctcttac tgtactagtc ttgtgctggt cacagtgtat cttat <sup>t</sup> atg cattacttg <sup>c</sup> ttccttgcat gattgtcttt atgcattcccc aatcttaatt gagaccatac ttgtataaga tttttgtaat atcttctgc tattggatat atttatttagt taatataattt atttatttt tgctattaat gtatttaatt ttttac	597 657 717 777 793
<210> 4	
<211> 151	
<212> PRT	
<213> Homo sapiens	
<400> 4	
Met Lys Ala Ser Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr 1 5 10 15	
Leu Leu Trp Thr Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser 20 25 30	

Cys Val Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp  
           35                  40                  45  
 Ile Arg Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile  
       50                  55                  60  
 Leu Arg Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys  
       65                  70                  75                  80  
 Cys Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys  
       85                  90                  95  
 Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu  
       100                  105                  110  
 Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys Leu Glu  
       115                  120                  125  
 Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu  
       130                  135                  140  
 Gln Trp Met Glu Glu Thr Glu  
       145                  150

<210> 5  
<211> 253  
<212> DNA  
<213> Homo sapiens

<400> 5  
ctttgaattc ctagctcctg tggctccag attcaggcc taagatgaaa gcctctagtc. 60  
ttgccttcag ccttctctct gctgcgtttt atctcctatg gactccttcc actggactga 120  
agacactcaa tttggaaagc tgtgtatcg ccacaaacct tcagggaaata cgaaatggat 180  
tttctgagat acggggcagt gtgcaagcca aagatggaaa cattgacatc agaatctaa 240  
ggaggactga gtc 253

<210> 6  
<211> 24  
<212> DNA  
<213> Homo sapiens

<400> 6  
attccttagct cctgtggtct ccag 24

<210> 7  
<211> 25  
<212> DNA  
<213> Homo sapiens

<400> 7  
ctctgctgcg ttttatctcc tatgg 25

<210> 8  
<211> 22  
<212> DNA  
<213> Homo sapiens

<400> 8  
tcccaaattg agtgtcttca gt

22

<210> 9  
<211> 45  
<212> DNA  
<213> Homo sapiens

<400> 9  
cacagcttcc caaaattgagt gtcttcagtc cagtggagg agtcc

45

<210> 10  
<211> 747  
<212> DNA  
<213> Homo sapiens

<400> 10  
ttttctgaca tacggggcag tgtgcaagcc aaagatggaa acattgacat cagaatctta 60  
aggaggactg agtcttgca agacacaaag cctgcgaatc gatgctgcct cctgcgccat 120  
ttgctaagac tctatctgga cagggtattt aaaaactacc agaccctga ccattatact 180  
ctccggaga tcagcagcct cgccaattcc tttcttacca tcaagaagga cctccggctc 240  
tgtcatgccc acatgacatcg ccattgtggg gaggaagcaa tgaagaaata cagccagatt 300  
ctgagtcaact ttgaaaagct ggaacctcag gcagcagttg tgaaggcttt ggggaaacta 360  
gacattcttc tgcaatggat ggaggagaca gaataggagg aaagtatgc tgctgctaag 420  
aatattcgag gtcaagagct ccagtcattca atacctgcag aggaggcatg accccaaacc 480  
accatctctt tactgtacta gtcttgcgt ggtcacagt tatcttattt atgcattact 540  
tgcttcctt catgattgtc ttatgcattt cccaatctta attgagacca tacttgata 600  
agattttgt aatatcttc tgctattgga tatattttt agttaatata tttattttt 660  
tttgcttattt aatgtattta atttttact tgggcatgaa actttaaaaaa aaattcacaa 720  
gattatattt ataacctgac tagagca 747

<210> 11  
<211> 614  
<212> DNA  
<213> Homo sapiens

<400> 11  
ttttctgaca tacggggcag tgtgcaagcc aaagatggaa acattgacat cagaatctta 60  
aggaggactg agtcttgca agacacaaag cctgcgaatc gatgctgcct cctgcgccat 120  
ttgctaagac tctatctgga cagggtattt aaaaactacc agaccctga ccattatact 180

ctccggaaga tcagcagcct cgccaattcc tttcttacca tcaagaagga cctccggctc	240
tgtctggaac ctcaggcgc agttgtgaag gctttggggg aactagacat tcttctgcaa	300
tggatggagg agacagaata ggaggaaagt gatgctgctg ctaagaatat tcgaggtaa	360
gagctccagt cttcaataacc tgcatgaggag gcatgaccctt aaaccacccat ctcttactg	420
tactagtctt gtgctggtca cagtgtatct tatttatgca ttacttgctt ccttgcata	480
ttgtctttat gcatacccaa tcttaattga gaccatactt gtataagatt tttgtatata	540
ctttctgcta ttggatataat ttatttagtta atatatttat ttatTTTtG ctattaatgt	600
attnaatttt ttac	614

&lt;210&gt; 12

&lt;211&gt; 152

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala Thr Asn Leu Gln	
1 . . . . . 5 . . . . . 10 . . . . . 15	
Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser Val Gln Ala Lys	
20 . . . . . 25 . . . . . 30	
Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr Glu Ser Leu Gln	
35 . . . . . 40 . . . . . 45	
Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg His Leu Leu Arg	
50 . . . . . 55 . . . . . 60	
Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr	
65 . . . . . 70 . . . . . 75 . . . . . 80	
Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys	
85 . . . . . 90 . . . . . 95	
Lys Asp Leu Arg Leu Cys His Ala His Met Thr Cys His Cys Gly Glu	
100 . . . . . 105 . . . . . 110	
Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe Glu Lys Leu	
115 . . . . . 120 . . . . . 125	
Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu	
130 . . . . . 135 . . . . . 140	
Leu Gln Trp Met Glu Glu Thr Glu	
145 . . . . . 150	

&lt;210&gt; 13

&lt;211&gt; 127

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala Thr Asn Leu Gln	
1 . . . . . 5 . . . . . 10 . . . . . 15	

Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser Val Gln Ala Lys  
20 25 30  
Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr Glu Ser Leu Gln  
35 40 45  
Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg His Leu Leu Arg  
50 55 60  
Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr  
65 70 75 80  
Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys  
85 90 95  
Lys Asp Leu Arg Leu Cys Leu Glu Pro Gln Ala Ala Val Val Lys Ala  
100 105 110  
Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu  
115 120 125

&lt;210&gt; 14

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile  
1 5 10 15

&lt;210&gt; 15

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr Thr  
1 5 10 15

&lt;210&gt; 16

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys  
1 5 10 15

&lt;210&gt; 17

&lt;211&gt; 15

&lt;212&gt; PRT

<213> Homo sapiens

<400> 17

Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met  
1 5 10 . 15

<210> 18

<211> 824

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (71) (598)

<400> 18

```

tgggagacat cgatagccct gattgatctc tttgaatttt cgcttctggc ctccaggatc 60
taggtgttaag atg aaa ggc ttt ggt ctt gcc ttt gga ctg ttc tcc gct 109
          Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala
          1           5           10

```

gtg ggt ttt ctt ctc tgg act cct tta act ggg ctc aag acc ctc cat 157  
Val Gly Phe Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His  
15 20 25

ttg gga agc tgt gtg att act gca aac cta cag gca ata caa aag gaa 205  
Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu  
30 35 . 40 45

ttt tct gag att cg<sup>g</sup> gat agt gtg caa gct gaa gat aca aat att gac 253  
Phe Ser Glu Ile Arg Asp Ser Val Gln Ala Glu Asp Thr Asn Ile Asp  
50 55 60

atc aga att tta agg acg act gag tct ttg aaa gac ata aag tct ttg  
 Ile Arg Ile Leu Arg Thr Thr Glu Ser Leu Lys Asp Ile Lys Ser Leu  
 65 70 75

gat agg tgc tgc ttc ctt cgt cat cta gtg aga ttc tat ctg gac agg 349  
Asp Arg Cys Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg  
80 85 90

gta ttc aaa gtc tac cag acc cct gac cac cat acc ctg aga aag atc 397  
 Val Phe Lys Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile  
 95 100 105

agc agc ctc gcc aac tcc ttt ctt atc atc aag aag gac ctc tca gtc Ser Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val 110 115 120 125	445
tgt cat tct cac atg gca tgt cat tgt ggg gaa gaa gca atg gag aaa Cys His Ser His Met Ala Cys His Cys Gly Glu Glu Ala Met Glu Lys 130 135 140	493
tac aac caa att ctg agt cac ttc ata gag ttg gaa ctt cag gca gcg Tyr Asn Gln Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala 145 150 155	541
gtg gta aag gct ttg gga gaa cta ggc att ctt ctg aga tgg atg gag Val Val Lys Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu 160 165 170	589
gag atg cta tagatgaaaag tggagaggct gctgagaaca ctccctgtcca Glu Met Leu 175	638
agaatctcag acctcagcac catgaagaca tggccccagg tgctggcatt tctactcaag agttccagtc ctcagcacca cgaagatggc ctcaaaccac caccctttg tgatataact tagtgctagc tatgtgtata ttatttctac attattggct cccttatgtg aatgcctca tgtgtc	698 758 818 824
<210> 19 <211> 176 <212> PRT <213> Mus musculus	
<400> 19 Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala Val Gly Phe 1 5 10 15 Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His Leu Gly Ser 20 25 30 Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu 35 40 45 Ile Arg Asp Ser Val Gln Ala Glu Asp Thr Asn Ile Asp Ile Arg Ile 50 55 60 Leu Arg Thr Thr Glu Ser Leu Lys Asp Ile Lys Ser Leu Asp Arg Cys 65 70 75 80 Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val Phe Lys 85 90 95 Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile Ser Ser Leu 100 105 110	

Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser  
 115 120 125  
 His Met Ala Cys His Cys Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln  
 130 135 140  
 Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys  
 145 150 155 160  
 Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met Leu  
 165 170 175

<210> 20  
 <211> 152  
 <212> PRT  
 <213> Mus musculus

<400> 20  
 Leu Lys Thr Leu His Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln  
 1 5 10 15  
 Ala Ile Gln Lys Glu Phe Ser Glu Ile Arg Asp Ser Val Gln Ala Glu  
 20 25 30  
 Asp Thr Asn Ile Asp Ile Arg Ile Leu Arg Thr Thr Glu Ser Leu Lys  
 35 40 45  
 Asp Ile Lys Ser Leu Asp Arg Cys Cys Phe Leu Arg His Leu Val Arg  
 50 55 60  
 Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp His His  
 65 70 75 80  
 Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys  
 85 90 95  
 Lys Asp Leu Ser Val Cys His Ser His Met Ala Cys His Cys Gly Glu  
 100 105 110  
 Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser His Phe Ile Glu Leu  
 115 120 125  
 Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Gly Ile Leu  
 130 135 140  
 Leu Arg Trp Met Glu Glu Met Leu  
 145 150

<210> 21  
 <211> 16  
 <212> PRT  
 <213> Mus musculus

<400> 21  
 Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu Ile Arg  
 1 5 10 15

<210> 22  
<211> 15  
<212> PRT  
<213> Mus musculus

<400> 22  
Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp His His Thr  
1 5 10 15

<210> 23  
<211> 15  
<212> PRT  
<213> Mus musculus

<400> 23  
Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys  
1 5 10 15

<210> 24  
<211> 15  
<212> PRT  
<213> Mus muculus

<400> 24  
Val Val Lys Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met  
1 5 10 15

<210> 25  
<211> 144  
<212> PRT  
<213> Mus muculus

<400> 25  
Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu  
1 5 10 15  
Ile Arg Asp Ser Val Gln Ala Glu Asp Thr Asn Ile Asp Ile Arg Ile  
20 25 30  
Leu Arg Thr Thr Glu Ser Leu Lys Asp Ile Lys Ser Leu Asp Arg Cys  
35 40 45

Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val Phe Lys  
50 55 60

Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile Ser Ser Leu  
65 70 75 80

Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser  
85 90 95

His Met Ala Cys His Cys Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln  
                  100                 105                 110  
 Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys  
                  115                 120                 125  
 Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met Leu  
                  130                 135                 140

<210> 26  
 <211> 144  
 <212> PRT  
 <213> Homo sapiens

<400> 26  
 Cys Val Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp  
  1              5                 10                 15  
 Ile Arg Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile  
  20             25                                 30  
 Leu Arg Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys  
  35             40                 45  
 Cys Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys  
  50             55                 60  
 Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu  
  65             70                 75                 80  
 Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His Ala  
  85             90                 95  
 His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln  
  100            105                 110  
 Ile Leu Ser His Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys  
  115            120                 125  
 Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu  
  130            135                 140

<210> 27  
 <211> 38  
 <212> PRT  
 <213> Homo sapiens

<400> 27  
 Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe  
  1              5                 10                 15  
 Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu  
  20             25                                 30  
 Asp Ile Leu Leu Gln Trp  
  35

<210> 28  
<211> 71  
<212> PRT  
<213> Homo sapiens

<400> 28

Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg  
1 5 10 15  
Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg  
20 25 30  
Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu  
35 40 45  
Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr  
50 55 60  
Gln Thr Pro Asp His Tyr Thr  
65 70

<210> 29

<211> 92

<212> PRT

<213> Homo sapiens

<400> 29

Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg  
1 5 10 15  
Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg  
20 25 30  
Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu  
35 40 45  
Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr  
50 55 60  
Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn  
65 70 75 80  
Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys  
85 90

<210> 30

<211> 82

<212> PRT

<213> Homo sapiens

<400> 30

Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu  
1 5 10 15

Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp  
20 25 30  
Leu Arg Leu Cys His Ala His Met Thr Cys His Cys Gly Glu Glu Ala  
35 40 45  
Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe Glu Lys Leu Glu Pro  
50 55 60  
Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln  
65 70 75 80  
Trp Met

<210> 31  
<211> 36  
<212> PRT  
<213> Homo sapiens

<400> 31  
Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu  
1 5 10 15  
Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp  
20 25 30  
Leu Arg Leu Cys  
35

<210> 32  
<211> 61  
<212> PRT  
<213> Homo sapiens

<400> 32  
Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His  
1 5 10 15  
Ala His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser  
20 25 30  
Gln Ile Leu Ser His Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val  
35 40 45  
Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met  
50 55 60

<210> 33  
<211> 756  
<212> DNA  
<213> Mus musculus

<220>

&lt;221&gt; CDS

&lt;222&gt; (71)...(532)

&lt;400&gt; 33

tgggagacat cgatagccct gattgatctc tttgaatttt cgcttctggc ctccaggatc 60  
 taggtgtaa atg aaa ggc ttt ggt ctt gcc ttt gga ctg ttc tcc gct 109  
 Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala  
 1 5 10

gtg ggt ttt ctt ctc tgg act cct tta act ggg ctc aag acc ctc cat 157  
 Val Gly Phe Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His  
 15 20 25

ttg gga agc tgt gtg att act gca aac cta cag gca ata caa aag gaa 205  
 Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu  
 30 35 40 45

ttt tct gag att cgg gat agt gtg tct ttg gat agg tgc tgc ttc ctt 253  
 Phe Ser Glu Ile Arg Asp Ser Val Ser Leu Asp Arg Cys Cys Phe Leu  
 50 55 60

cgt cat cta gtg aga ttc tat ctg gac agg gta ttc aaa gtc tac cag 301  
 Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln  
 65 70 75

acc cct gac cac cat acc ctg aga aag atc agc agc ctc gcc aac tcc 349  
 Thr Pro Asp His His Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser  
 80 85 90

ttt ctt atc atc aag aag gac ctc tca gtc tgt cat tct cac atg gca 397  
 Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser His Met Ala  
 95 100 105

tgt cat tgt ggg gaa gaa gca atg gag aaa tac aac caa att ctg agt 445  
 Cys His Cys Gly Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser  
 110 115 120 125

cac ttc ata gag ttg gaa ctt cag gca gcg gtg gta aag gct ttg gga 493  
 His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly  
 130 135 140

gaa cta ggc att ctt ctg aga tgg atg gag gag atg cta tagatgaaag 542  
 Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met Leu  
 145 150

tggataggct gctgagaaca	ctcctgtcca	agaatctcag	acccgcac	catgaagaca	602
tggccccagg	tgctggcatt	tctactcaag	agttccagtc	ctcagcacca	662
ctcaaaccac	caccccttg	tgatataact	tagtgcgtac	tatgtgtata	722
attattggct	cccttatgt	aatgcctca	tgtg		756

<210> 34  
<211> 154  
<212> PRT  
<213> Mus musculus

&lt;400&gt; 34

Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala Val Gly Phe					
1	5	10	15		
Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His Leu Gly Ser					
20	25	30			
Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu					
35	40	45			
Ile Arg Asp Ser Val Ser Leu Asp Arg Cys Cys Phe Leu Arg His Leu					
50	55	60			
Val Arg Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp					
65	70	75	80		
His His Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Ile					
85	90	95			
Ile Lys Lys Asp Leu Ser Val Cys His Ser His Met Ala Cys His Cys					
100	105	110			
Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser His Phe Ile					
115	120	125			
Glu Leu Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Gly					
130	135	140			
Ile Leu Leu Arg Trp Met Glu Glu Met Leu					
145	150				

<210> 35  
<211> 130  
<212> PRT  
<213> Mus musculus

&lt;400&gt; 35

Leu Lys Thr Leu His Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln					
1	5	10	15		
Ala Ile Gln Lys Glu Phe Ser Glu Ile Arg Asp Ser Val Ser Leu Asp					
20	25	30			
Arg Cys Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val					
35	40	45			

Phe Lys Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile Ser  
 50 55 60  
 Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys  
 65 70 75 80  
 His Ser His Met Ala Cys His Cys Gly Glu Ala Met Glu Lys Tyr  
 85 90 95  
 Asn Gln Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val  
 100 105 110  
 Val Lys Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu  
 115 120 125  
 Met Leu  
 130

<210> 36  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 36  
agattctatc tggacagggt attcaaa

27

<210> 37  
<211> 17  
<212> DNA  
<213> Homo sapiens

<400> 37  
gcgaggctga tctttct

17

<210> 38  
<211> 25  
<212> DNA  
<213> Mus musculus

<400> 38  
tggcgaggct gctgatctt ctcag

25

<210> 39  
<211> 25  
<212> DNA  
<213> Mus musculus

<400> 39  
ctttatgtct ttcaaagact cagtc

25

<210> 40  
<211> 26  
<212> DNA  
<213> Mus musculus

<400> 40  
catcagaatt ttaaggacga ctgagt

26

<210> 41  
<211> 25  
<212> DNA  
<213> Mus musculus

<400> 41  
ggtgttcagg ggtctggtag acttt

25

<210> 42  
<211> 23  
<212> DNA  
<213> Mus musculus

<400> 42  
ggtgcatatt cctggtagct aga

23

<210> 43  
<211> 25  
<212> DNA  
<213> Mus musculus

<400> 43  
attgcagtgt aaggaaatac agaga

25

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/25228

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6	C12N15/19	C07K14/52	C07K16/24	C07K16/42	A61K38/19
	A61K48/00	A01K67/027			

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C07K A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ROHOVSKY S. AND D'AMORE P.A.: "Growth factors and angiogenesis in wound healing" GROWTH FACTORS WOUND HEALING. EDS: ZIEGLER T.R., PIERCE G.F., HERNDON D.N.; PUB: SPRINGER NEW YORK N.Y., 1997, pages 8-26, XP002099410	
A	DLAVIN J.: "Cytokines and tissue repair" EOS - J. IMMUNOL. IMMUNOPHARMACOL., vol. XVII, no. 1, 1997, pages 25-29, XP002099411	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

12 April 1999

22/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G